Enzon Pharmaceuticals, Inc.
The company, Enzon Pharmaceuticals, Inc., has no significant operations. It previously marketed PegIntron, had a marketing agreement for Vicineum, and held licensing agreements for SC Oncaspar and other drugs. The company was formerly known as Enzon, Inc. and changed its name in 2002.
Overview
Strengths
- Current Price to Earnings Ratio (5.41) is lower than the sector mean (101.19)
- Price to book ratio (2.12) is lower than the sector mean (23.22)
- The company has high returns. ROIC (18.82%) is higher than the sector mean (-46.31%)
- Price to free cash flow (5.69) is lower than the sector mean (102.27)
Weaknesses
- With a depreciation Potential of -100.00% , based on our advanced cash flow analysis, it suggests the stock may be overvalued
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (41.75) is higher than the sector mean (-0.04)
- EV/EBITDA (34.64) is significantly higher than the sector mean (-2.03)
- EBITDA Margin (0.00%) appears relatively low
Key Financial Data
| Indicator | Value |
|---|
| PER | 8.3 |
| EV/EBITDA | 27.9 |
| Price/Free Cash Flow' | 5.8 |
| ROIC | 17.6% |
| Net Debt/EBITDA | 32.8 |